12 results
To investigate the effects of galantamine on cognitive impairment and visual hallucinations in Parkinson`s disease, both therapeutic (direct effect) and preventive (protection against an acute increase of dopaminergic medication used by the patient…
To replicate and extend the findings of the recent methylphenidate study in which methylphenidate was found to enhance episodic memory performance; To explore whether this effect of methylphenidate is primarily mediated by its dopaminergic action.
To prospectively explore the feasibility safety, tolerability, preliminary efficacy, costs, and pharmacokinetic profile of repetitive ePIPAC-OX as a palliative monotherapy for isolated unresectable colorectal PM under controlled circumstances.
This is a medical-scientific research study. The purpose of the study is to investigate the effect of multiple doses of the study compound BIA 28-6156 on the pharmacokinetics of the drugs levodopa-carbidopa (Group 1) and levodopa-benserazide (Group…
Primary Objective:* To evaluate ORR of avelumab in combination with talazoparib, in patients with locally advanced or metastatic solid tumors harboring BRCA1, BRCA2 or ATM defect.Secondary Objective:* To assess the overall safety and tolerability of…
The aim of this study is to improve our understanding of the mechanisms underlying altered social performance monitoring from a pharmacological perspective by directly comparing the effects of dopamine and oxytocin on individual and social…
to assess whether a single-dose of levodopa improves cognitive symptoms and balances goal-directed and habitual behavior.
The study consists of two phases. In the first phase, we aim to investigate whether the dopamine receptor D4 (DRD4) genotype confers differential susceptibility to the effects of early life stress on empathy and prosocial behavior more generally in…
To prove that the RECAP test has the potential of selecting patients who are sensitive to treatment with the PARP inhibitor talazoparib as measured by the PFS rate at 4 months.
Primary objectiveTo demonstrate that talazoparib in combination with enzalutamide is superior to placebo in combination with enzalutamide in prolonging investigator--assessed Radiographic Progression-free Survival (rPFS), in participants with mCSPC…
PrimaryTo evaluate the efficacy of single agent talazoparib in DNA damage repair (DDR) + metastatic CRPC, as measured by best objective responserate (ORR).Secondary:To evaluate efficacy with respect to the following parameters:• Time to objective…
To investigate whether early treatment with levodopa has a delayed beneficial effect on PD symptoms and functional health, and improves the ability to (maintain) work, reduces the use of (informal) care, caregiver burden, and costs. Additionally,…